Magic Shave Powder Gold's Affects on the Occurrence of Pseudofolliculitis Barbae

Pseudofolliculitis Barbae Clinical Trial

Official title:

Depilatory Cream's Affect on the Occurrence of Pseudofolliculitis Barbae

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04220502
• Other study ID #: WayneMed
• Status: Withdrawn
• Phase: Early Phase 1
• Start date: August 1, 2020
• Est. completion date: May 3, 2022

Study information

• Verified date: May 2022
• Source: Wayne State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Comparing the amount of papules, macules, pustules, and irritation caused by pseudofolluculitis barbae in subjects using depilatory cream versus traditional shaving methods.

Description:

Comparing an experimental group that will remove facial hair with magic shave powder gold, and a control group that will continue using traditional shaving methods. Both the subject and a physician will make observations to determine the efficacy of depilatory creams in reducing pseudofolliculits barbae.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 3, 2022
• Est. primary completion date: May 3, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male

• PFB patient

Exclusion Criteria:

• Failed sensitivity testing

Related Conditions & MeSH terms

• Pseudofolliculitis Barbae

Intervention

Drug:
• Magic Shave Powder Gold
Depilatory Cream for facial hair removal

Device:
• Traditional Shaving Methods
Continued facial hair removal using traditional razors

Locations

Country	Name	City	State
United States	Wayne State University Physician Group Dermatology	Dearborn	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Wayne State University

Country where clinical trial is conducted

United States, 

References & Publications (2)

Daniel A, Gustafson CJ, Zupkosky PJ, Candido A, Kemp HR, Russell G, McMichael A. Shave frequency and regimen variation effects on the management of pseudofolliculitis barbae. J Drugs Dermatol. 2013 Apr;12(4):410-8. — View Citation

Kindred C, Oresajo CO, Yatskayer M, Halder RM. Comparative evaluation of men's depilatory composition versus razor in black men. Cutis. 2011 Aug;88(2):98-103. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Investigator Global Assessment	Difference in the investigator assessment of lesions and irritation at baseline and 12 weeks, measured by investigator. The scale title is Investigator Global Assessment, the minimum value is 0, the maximum is 5. Higher scores mean worse outcome.	12 weeks
Secondary	Patient Global Assessment	Difference in the investigator assessment of disease symptoms at baseline and 12 weeks, measured by patient. The scale title is Patient Global Assessment, the minimum value is 0, the maximum is 5. Higher scores mean worse outcome.	12 weeks